Most Read Articles
6 days ago
In patients with type 2 diabetes, obesity may be protective against vision-threatening diabetic retinopathy, a recent Korea study has shown.
Yesterday
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
Roshini Claire Anthony, 6 days ago

Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.

6 days ago
The use of opioids may have limited long-term efficacy in the management of chronic noncancer pain, reports a new study.

Hypertension and cholesterol lowering interventions do not reduce cognitive decline

Roshini Claire Anthony
22 Nov 2016

Blood pressure lowering medications and statins do not prevent cognitive and functional decline in elderly patients, according to results of the HOPE-3 trial* presented at the Scientific Sessions of the American Heart Association (AHA 2016) held recently in New Orleans, Louisiana, US.

To study the impact of lipid and blood pressure lowering interventions on changes in cognitive function, researchers of this multicentre trial (228 centres in 21 countries) randomized 12,705 participants to receive the blood pressure lowering drugs candesartan/hydrochlorothiazide or placebo and the cholesterol lowering drug rosuvastatin or placebo. [AHA 2016; LBCT 01]

Of the 3,086 individuals aged ≥70 years (mean age 74 years, 59 percent women) with an intermediate risk of cardiovascular disease, 2,361 completed a baseline questionnaire and were followed up for an average duration of 5.7 years. At study conclusion, 2,142 patients were alive, 76 percent (n=1,626) of whom completed both baseline and study end questionnaires.

The primary outcome was the decline in processing speed as measured by the Digit Symbol Substitution Test (DSST), while the decline in executive function and increase in psychomotor speed (secondary outcomes) were measured using a modified version of the Montreal Cognitive Assessment (mMoCA) and Trail Making Test Part B (TMT-B), respectively.

Participants in both groups experienced cognitive decline though there were no between-group differences. The changes in mean DSST score were 0.1 (p=0.86) for those on blood pressure lowering medication vs placebo, -0.5 (p=0.38) for those on rosuvastatin vs placebo, and -0.4 (p=0.63) for those on both blood pressure lowering medications and rosuvastatin vs double placebo.

The study also found that rosuvastatin did not appear to have an adverse effect on cognitive function. Subgroup analysis found that a longer duration of blood pressure lowering intervention was associated with less cognitive decline, a finding that requires further study, according to the researchers. 

“There was no difference in mental processing speed, in executive function, in psychomotor speed, or other cognitive or functional areas tested between the groups,” said Dr Jackie Bosch from the Population Health Research Institute, McMaster University and Hamilton Health Sciences in Hamilton, Ontario, Canada, who presented the results on behalf of the HOPE-3 researchers.

“We know that blood pressure effects begin in middle-age. We need to think about treating earlier and treating longer to affect cognitive function, especially for individuals at higher cardiovascular risk,” she said.

 

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
In patients with type 2 diabetes, obesity may be protective against vision-threatening diabetic retinopathy, a recent Korea study has shown.
Yesterday
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
Roshini Claire Anthony, 6 days ago

Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.

6 days ago
The use of opioids may have limited long-term efficacy in the management of chronic noncancer pain, reports a new study.